美诺华(603538.SH)子公司获得厄贝沙坦氢氯噻嗪片药品注册证书

Core Viewpoint - Meinuo Pharma (603538.SH) has received approval from the National Medical Products Administration for its product, Irbesartan Hydrochlorothiazide Tablets, which is indicated for the treatment of primary hypertension [1] Company Summary - Meinuo Pharma's wholly-owned subsidiary, Ningbo Meinuo TianKang Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Irbesartan Hydrochlorothiazide Tablets [1] - The drug is a combination of the angiotensin II receptor antagonist Irbesartan and the thiazide diuretic Hydrochlorothiazide, which work synergistically to lower blood pressure within the recommended therapeutic dosage range [1]